Needham analyst Serge Belanger lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $78 from $80 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Analyst Reaffirms Buy on Xenon, Citing Blockbuster Potential for Lead Epilepsy Candidate and Upside from Pipeline Programs
- Xenon Highlights Positive Phase 3 Azetukalner Seizure Data
- Xenon Pharmaceuticals reports Q1 EPS ($1.17), consensus ($1.20)
- XENE Upcoming Earnings Report: What to Expect?
- Xenon’s Azetukalner: Rapid, Durable Efficacy and Once‑Daily Convenience Underpin Buy Rating and Preferred Second‑Line Epilepsy Positioning